Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial Comparing Bendamustine and Melphalan With Melphalan Alone as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Myeloma Patients

NCT03187223 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT03187223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03187223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial Comparing Bendamustine and Melphalan With Melphalan Alone as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Myeloma Patients
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Phase 2
Overall status
Completed
Start date
July 20, 2017
Completion date
May 28, 2020
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma